{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:04:07Z","timestamp":1778951047095,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.det.2015.11.004","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T05:45:44Z","timestamp":1453787144000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety Considerations and Monitoring in Patients Treated with Systemic Medications for Acne"],"prefix":"10.1016","volume":"34","author":[{"given":"Hyunhee","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Skopit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2015.11.004_bib1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0190-9622(92)70135-3","article-title":"The prevalence of acne on the basis of physical examination","volume":"26","author":"Stern","year":"1992","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.004_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systemic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.det.2015.11.004_bib3","first-page":"1407","article-title":"Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications","volume":"9","author":"Kircik","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.7.5.571","article-title":"The use and safety of doxycycline hyclate and other second generation tetracyclines","volume":"7","author":"Sloan","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.det.2015.11.004_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000250830","article-title":"Minocycline versus doxycycline in the treatment of acne vulgaris: a double-blind study","volume":"157","author":"Smit","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.det.2015.11.004_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/09546638909086681","article-title":"Doxycycline versus minocycline in the treatment of acne vulgaris: a double-blind study","volume":"1","author":"Olafsson","year":"1989","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2015.11.004_bib7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2230.1988.tb00689.x","article-title":"A\u00a0comparison of doxycycline and minocycline in the treatment of acne vulgaris","volume":"13","author":"Harrison","year":"1988","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","article-title":"Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis","volume":"62","author":"Shaughnessy","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.11.004_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0049-0172(99)80004-3","article-title":"Minocycline-induced autoimmune syndromes: an overview","volume":"28","author":"Elkayam","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.det.2015.11.004_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jpeds.2008.03.013","article-title":"Chronic minocycline-induced autoimmunity in children","volume":"153","author":"El-Hallak","year":"2008","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.det.2015.11.004_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000112926","article-title":"Minocycline-induced DRESS: evidence for accumulation of the culprit drug","volume":"216","author":"Maubec","year":"2008","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.det.2015.11.004_bib13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archderm.1997.03890460044005","article-title":"Comparative safety of tetracycline, minocycline, and doxycycline","volume":"133","author":"Shapiro","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/j.1552-4604.1988.tb03160.x","article-title":"A\u00a0double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R","volume":"28","author":"Berger","year":"1988","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.det.2015.11.004_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00265856","article-title":"Doxycycline tolerance study. Incidence of nausea after doxycycline administration to healthy volunteers: a comparison of 2 formulations (Doryx vs Vibramycin)","volume":"40","author":"Story","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.det.2015.11.004_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00044011-199510060-00002","article-title":"Enteric coating reduces upper gastrointestinal adverse reactions to doxycycline","volume":"10","author":"Jarvinen","year":"1995","journal-title":"Clin Drug Invest"},{"issue":"4","key":"10.1016\/j.det.2015.11.004_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2310\/7750.2013.12085","article-title":"Doxycycline-induced cutaneous inflammation with systemic symptoms in a patient with acne vulgaris","volume":"17","author":"Weinstein","year":"2013","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.det.2015.11.004_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/SMJ.0b013e31818f98f0","article-title":"Doxycycline-induced pseudotumor cerebri","volume":"102","author":"Tabibian","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.det.2015.11.004_bib19","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1212\/WNL.62.12.2297","article-title":"Doxycycline and intracranial hypertension","volume":"62","author":"Friedman","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.det.2015.11.004_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000119753","article-title":"Severe drug hypersensitivity reaction in a young woman treated with doxycycline","volume":"217","author":"Robles","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2015.11.004_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.annder.2009.10.180","article-title":"Severe drug hypersensitivity reaction (DRESS syndrome) to doxycycline","volume":"137","author":"Mailhol","year":"2010","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000017847","article-title":"Systemic antibiotics for acne","volume":"196","author":"Meynadier","year":"1998","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.det.2015.11.004_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00128071-200304050-00002","article-title":"Antibacterial therapy for acne. A guide to selection and use of systemic agents","volume":"4","author":"Tan","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0140-6736(92)92810-3","article-title":"Minocycline related lupus","volume":"340","author":"Matsuura","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.det.2015.11.004_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archinte.159.5.493","article-title":"Minocycline and lupuslike syndrome in acne patients","volume":"159","author":"Sturkenboom","year":"1999","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.det.2015.11.004_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000018387","article-title":"Minocycline-induced lupus: a systematic review","volume":"200","author":"Schlienger","year":"2000","journal-title":"Dermatology"},{"issue":"8","key":"10.1016\/j.det.2015.11.004_bib27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1177\/00912700122010753","article-title":"The risk of liver damage associated with minocycline: a comparative study","volume":"41","author":"Seaman","year":"2001","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.det.2015.11.004_bib28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1378\/chest.115.5.1471","article-title":"Respiratory distress due to minocycline-induced pulmonary lupus","volume":"115","author":"Christodoulou","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.det.2015.11.004_bib29","first-page":"640","article-title":"Doxycycline and photosensitivity","volume":"100","author":"Edwards","year":"1987","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.det.2015.11.004_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000247308","article-title":"Acute generalized exanthematous pustulosis due to doxycycline","volume":"186","author":"Trueb","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2015.11.004_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0733-8635(05)70405-8","article-title":"Antiandrogen and hormonal treatment of acne","volume":"14","author":"Shaw","year":"1996","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2015.11.004_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","volume":"111","author":"Goodfellow","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2133.1985.tb02305.x","article-title":"Oral spironolactone therapy for female patients with acne, hirsutisum or androgenic alopecia","volume":"112","author":"Burke","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","volume":"115","author":"Muhlemann","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0190-9622(91)70034-Y","article-title":"Spironolactone in dermatologic therapy","volume":"24","author":"Shaw","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.1988.tb02571.x","article-title":"Tolerance of spironolactone","volume":"118","author":"Hughes","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1067\/mjd.2000.105557","article-title":"Low-dose adjunctive spironolactone in the treatmet of acne in women: a retrospective analysis of 85 consecutively treated patients","volume":"43","author":"Shaw","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","article-title":"Effects and side-effects of spironolactone therapy in women with acne","volume":"19","author":"Yemisci","year":"2005","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1365-2265.2003.16911.x","article-title":"Different effectiveness of cyproterone acetate doses in treatment of acne","volume":"58","author":"De Leo","year":"2003","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.det.2015.11.004_bib40","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.004_bib41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/archderm.134.9.1162-a","article-title":"Adverse effects of spironolactone therapy in women with acne","volume":"134","author":"Lubbos","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib42","series-title":"Rook\/Wilkinson\/Ebling textbook of dermatology","first-page":"1927","article-title":"Disorders of the sebaceous glands","author":"Cunliffe","year":"1998"},{"issue":"3","key":"10.1016\/j.det.2015.11.004_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/S0365-05962010000300006","article-title":"Evaluation of clinical adverse effects and laboratory alterations in patients with acne vulgaris treated with oral isotretinoin","volume":"85","author":"Brito","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2165\/00003495-199753030-00003","article-title":"Current use and future potential role of retinoid drugs in dermatology","volume":"53","author":"Orfanos","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.det.2015.11.004_bib45","first-page":"2810","article-title":"The retinoids","volume":"vol. 2","author":"Peck","year":"1999"},{"key":"10.1016\/j.det.2015.11.004_bib46","series-title":"Dermatologia","author":"Sampaio","year":"2001"},{"key":"10.1016\/j.det.2015.11.004_bib47","series-title":"Dermatologia","author":"Azulay","year":"2004"},{"issue":"7","key":"10.1016\/j.det.2015.11.004_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archdermatol.2012.352","article-title":"Ocular adverse effects of systemic treatment with isotretinoin","volume":"148","author":"Neudorfer","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.11.004_bib49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9394(01)01024-8","article-title":"Ocular side effects possibly associated with isotretinoin usage","volume":"132","author":"Fraunfelder","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.det.2015.11.004_bib50","first-page":"429","article-title":"Ocular side effects of accutane therapy","volume":"9","author":"Lerman","year":"1992","journal-title":"Lens Eye Toxic Res"},{"issue":"3","key":"10.1016\/j.det.2015.11.004_bib51","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/sder.2001.28209","article-title":"Safety issues in isotretinoin therapy","volume":"20","author":"Hanson","year":"2001","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.det.2015.11.004_bib52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archderm.1983.01650340018012","article-title":"Pyogenic granuloma like acne lesions during isotretinoin therapy","volume":"119","author":"Exner","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000029843","article-title":"The effect of isotretinoin on biotinidase activity","volume":"12","author":"Schulpis","year":"1999","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"10.1016\/j.det.2015.11.004_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0733-8635(05)70252-7","article-title":"The use of retinoids in the pediatric patient","volume":"16","author":"Ruiz-Maldonado","year":"1998","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.det.2015.11.004_bib55","series-title":"Accutane (isotretinoin) capsules, in physicians\u2019 desk reference","first-page":"2610","author":"Roche Laboratories Inc","year":"2000"},{"key":"10.1016\/j.det.2015.11.004_bib56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0190-9622(86)70167-9","article-title":"Atypical keloids after dermabrasion of patients taking isotretinoin","volume":"15","author":"Rubenstein","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib57","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2133.1988.tb02574.x","article-title":"Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment","volume":"118","author":"Zachariae","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib58","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0190-9622(98)70011-8","article-title":"Uses of vitamins A, C, and E and related compounds in dermatology: a review","volume":"39","author":"Keller","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2133.2001.04103.x","article-title":"What is the cumulative effects or long-term, low-dose isotretinoin on the development of DISH?","volume":"144","author":"Ling","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0190-9622(82)70148-3","article-title":"Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid","volume":"7","author":"Milstone","year":"1982","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib61","first-page":"94","article-title":"Muscular damage during isotretinoin treatment","volume":"125","author":"Heudes","year":"1998","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib62","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2340\/0001555572352354","article-title":"Comparison of muscle-derived serum carbonic anhydrase III and myoglobin in dermatological patients: effects of isotretinoin treatment","volume":"72","author":"Oikarinen","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib63","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0248-8663(96)80763-6","article-title":"Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isotretinoin therapy","volume":"16","author":"Aurousseau","year":"1995","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.det.2015.11.004_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1468-3083.2000.00061-10.x","article-title":"Acute appendicitis and isotretinoin: a coincidence?","volume":"14","author":"Azon-Masoliver","year":"2000","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib65","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-4362.1996.tb01675.x","article-title":"Acute esophagitis caused by isotretinoin","volume":"35","author":"Amichai","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib66","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/j.1572-0241.1999.02568.x","article-title":"Isotretinoin: possible component cause of inflammatory bowel disease","volume":"94","author":"Prokop","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.det.2015.11.004_bib67","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2133.1990.tb01483.x","article-title":"Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease","volume":"123","author":"Godfrey","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0890-6238(93)90273-A","article-title":"Neurobehavioral tertology of isotretinoin","volume":"7","author":"Adams","year":"1998","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.det.2015.11.004_bib69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2230.1995.tb01297.x","article-title":"Abnormal night vision with isotretinoin therapy for acne","volume":"20","author":"Maclean","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1526-4610.1989.hed2907441.x","article-title":"Drug-related headache","volume":"29","author":"Askmark","year":"1989","journal-title":"Headache"},{"key":"10.1016\/j.det.2015.11.004_bib71","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0190-9622(85)80374-1","article-title":"Exercise-induced bronchoconstriction related to isotretinoin therapy","volume":"13","author":"Fisher","year":"1985","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1365-2133.2000.03324.x","article-title":"Exacerbation of asthma by isotretinoin","volume":"142","author":"Kapur","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib73","unstructured":"RxList.com [homepage]. Available at: http:\/\/www.rxlist.com\/cgi\/generic\/isotret_ad.htm. Accessed Augest 12, 2014."},{"key":"10.1016\/j.det.2015.11.004_bib74","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/ndt\/12.6.1299a","article-title":"Renal impairment induced by isotretinoin","volume":"12","author":"Pavese","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.det.2015.11.004_bib75","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2340\/0001555577330","article-title":"Urethritis associated with\u00a0isotretinoin therapy","volume":"77","author":"Edwards","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib76","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jama.279.14.1057-JMN0408-2-1","article-title":"Acne drug depression warnings highlight need for expert care","volume":"279","author":"Lamberg","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.det.2015.11.004_bib77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJM200102083440616","article-title":"Depression and suicide in patients treated with isotretinoin","volume":"344","author":"Wysowski","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2015.11.004_bib78","first-page":"134","article-title":"Isotretinoin, depression and suicide: a review of evidence","volume":"55","author":"Magin","year":"2005","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.det.2015.11.004_bib79","first-page":"1102","article-title":"Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide","volume":"137","author":"Jick","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1468-3083.1999.tb01042.x","article-title":"The inter-relationship between isotretinoin\/acne and depression","volume":"12","author":"Chu","year":"1999","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib81","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1067\/mjd.2001.113719","article-title":"Analysis of common side effects of isotretinoin","volume":"45","author":"McLane","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib82","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0190-9622(82)70054-4","article-title":"Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids","volume":"6","author":"Kamm","year":"1982","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib83","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0190-9622(88)70165-6","article-title":"Liver toxicity of retinoid therapy","volume":"19","author":"Roenigk","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib84","series-title":"Comprehensive dermatologic drug therapy","first-page":"269","article-title":"Systemic retinoids","author":"Nguyen","year":"2001"},{"key":"10.1016\/j.det.2015.11.004_bib85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2133.1985.tb02293.x","article-title":"A\u00a0sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins","volume":"112","author":"Vahlquist","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1542\/peds.90.1.119","article-title":"American academy of pediatrics committee on drugs: retinoid therapy for severe dermatological disorders","volume":"90","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.det.2015.11.004_bib87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7326\/0003-4819-107-1-63","article-title":"Pancreatitis associated with isotretinoin-induced hypertriglyceridemia","volume":"107","author":"Flynn","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2015.11.004_bib88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/0001555566144148","article-title":"Changes in laboratory variables induced by isotretinoin treatment of acne","volume":"66","author":"Michaelsson","year":"1986","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib89","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1365-2133.1992.tb00679.x","article-title":"Staphylococcus aureus and intranasal mupicorin in patients receiving isotretinoin for acne","volume":"126","author":"Williams","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib90","series-title":"Comprehensive dermatologic drug therapy","first-page":"276","article-title":"Systemic retinoids","author":"Patton","year":"2007"},{"key":"10.1016\/j.det.2015.11.004_bib91","series-title":"Manual of dermatologic therapeutics","first-page":"3","article-title":"Acne","author":"Batra","year":"2007"},{"key":"10.1016\/j.det.2015.11.004_bib92","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1468-3083.2006.01784.x","article-title":"The effectiveness of intermittent isotretinoin treatment in mild or moderate acne","volume":"20","author":"Kaymak","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib93","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00403-007-0777-2","article-title":"Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study","volume":"299","author":"Akman","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.det.2015.11.004_bib94","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2005.11.1061","article-title":"Low-dose isotretinoin in the treatment of acne vulgaris","volume":"54","author":"Amchai","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib95","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1468-3083.2008.03022.x","article-title":"Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris","volume":"23","author":"Sardana","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.11.004_bib96","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0377-1237(10)80038-3","article-title":"Toxicity of low-dose intermittent isotretinoin in recalcitrant acne","volume":"66","author":"Kumar","year":"2010","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.det.2015.11.004_bib97","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000057887","article-title":"A\u00a0proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris","volume":"204","author":"Altman","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2015.11.004_bib98","first-page":"273","article-title":"Isotretinoin therapy: any need for laboratory assessment?","volume":"23","author":"Tallab","year":"2004","journal-title":"West Afr J Med"},{"key":"10.1016\/j.det.2015.11.004_bib99","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1067\/mjd.2001.113717","article-title":"Uses and complications of isotretinoin therapy","volume":"45","author":"Ellis","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.004_bib100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/095466301750163509","article-title":"Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests?","volume":"12","author":"Alcalay","year":"2001","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2015.11.004_bib101","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archderm.135.8.961","article-title":"Bone densities in patients receiving isotretinoin for cystic acne","volume":"135","author":"Leachman","year":"1999","journal-title":"Arch Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T23:46:28Z","timestamp":1718322388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0733863515001436"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.11.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Considerations and Monitoring in Patients Treated with Systemic Medications for Acne","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}